Tailoring transplant drugs to fight cancer, not the patient
NCT ID NCT03555851
Summary
This study aims to improve stem cell transplants for adults with leukemia. Researchers want to see if they can personalize the dose of a key drug (cyclophosphamide) based on a patient's genetics and how their body processes the medication. The goal is to help the transplant fight the cancer more effectively while reducing serious side effects like graft-versus-host disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA, NOT OTHERWISE SPECIFIED are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Levine Cancer Institute
RECRUITINGCharlotte, North Carolina, 28204, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.